2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Sell
24
MOLN Quote, Financials, Valuation and Earnings
Last price:
$4.09
Seasonality move
:
-25.38%
Day range:
$4.33 - $4.35
52-week range:
$3.32 - $12.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.67x
P/B ratio:
1.02x
Volume:
581
Avg. volume:
2.5K
1-year change:
12.03%
Market cap:
$159.7M
Revenue:
$5.6M
EPS (TTM):
-$1.81
Analysts' Opinion
-
Consensus RatingMolecular Partners AG has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.78, Molecular Partners AG has an estimated upside of 148.97% from its current price of $4.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.13 representing 100% downside risk from its current price of $4.33.
Fair Value
-
According to the consensus of 4 analysts, Molecular Partners AG has 148.97% upside to fair value with a price target of $10.78 per share.
MOLN vs. S&P 500
-
Over the past 5 trading days, Molecular Partners AG has underperformed the S&P 500 by -11.56% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Molecular Partners AG does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Molecular Partners AG revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Molecular Partners AG reported revenues of $787.5K.
Earnings Growth
-
Molecular Partners AG has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Molecular Partners AG reported earnings per share of -$0.34.
Enterprise value:
-5.7M
EV / Invested capital:
--
Price / LTM sales:
21.67x
EV / EBIT:
--
EV / Revenue:
-0.84x
PEG ratio (5yr expected):
-0.26x
EV / Free cash flow:
0.08x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-33.67%
Net Income Margin (TTM):
-1043.02%
Return On Equity:
-37.36%
Return On Invested Capital:
-37.36%
Operating Margin:
-2142.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $204.5M | $7.8M | -- | $1.2M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $127.9M | -$68M | -$69.5M | -$18.8M | -$16.8M | |
| EBITDA | $132.3M | -$66.3M | -$58.7M | -$21.6M | -$12.1M | |
| Diluted EPS | $3.87 | -$2.10 | -$1.81 | -$0.68 | -$0.34 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $203.5M | $179.6M | $274.8M | $229.1M | $170.8M | |
| Total Assets | $214.7M | $188.9M | $282.9M | $236.1M | $175.5M | |
| Current Liabilities | $66M | $51.3M | $18.6M | $17.2M | $11.9M | |
| Total Liabilities | $91.9M | $71.5M | $29.2M | $26.1M | $18.7M | |
| Total Equity | $122.7M | $117.4M | $253.6M | $210M | $156.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $124.3M | -$65.7M | -$67.3M | -$17M | -$14.1M | |
| Cash From Investing | -$106M | $49.7M | $46M | $21.2M | -$6M | |
| Cash From Financing | -$1.6M | -$1.3M | $16.4M | -$315.7K | $17.4M | |
| Free Cash Flow | $122.8M | -$66.6M | -$68.1M | -$17.3M | -$14.2M | |
MOLN
Sector
Market Cap
$159.7M
$37.4M
Price % of 52-Week High
34.09%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
12.03%
-38.36%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$4.65
200-day SMA
Sell
Level
$5.61
Bollinger Bands (100)
Sell
Level
4.86 - 5.84
Chaikin Money Flow
Buy
Level
1.3M
20-day SMA
Sell
Level
$4.80
Relative Strength Index (RSI14)
Sell
Level
33.46
ADX Line
Sell
Level
22.63
Williams %R
Buy
Level
-92.7711
50-day SMA
Sell
Level
$5.04
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
5.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4065)
Buy
CA Score
(Annual)
Level (-0.0035)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (4.231)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Stock Forecast FAQ
In the current month, MOLN has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MOLN average analyst price target in the past 3 months is $10.78.
-
Where Will Molecular Partners AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Molecular Partners AG share price will rise to $10.78 per share over the next 12 months.
-
What Do Analysts Say About Molecular Partners AG?
Analysts are divided on their view about Molecular Partners AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Molecular Partners AG is a Sell and believe this share price will drop from its current level to $5.13.
-
What Is Molecular Partners AG's Price Target?
The price target for Molecular Partners AG over the next 1-year time period is forecast to be $10.78 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MOLN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Molecular Partners AG is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MOLN?
You can purchase shares of Molecular Partners AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Molecular Partners AG shares.
-
What Is The Molecular Partners AG Share Price Today?
Molecular Partners AG was last trading at $4.09 per share. This represents the most recent stock quote for Molecular Partners AG. Yesterday, Molecular Partners AG closed at $4.33 per share.
-
How To Buy Molecular Partners AG Stock Online?
In order to purchase Molecular Partners AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Is Goldman Sachs Stock a Buy Sell or Hold?
When the Federal Reserve started hiking rates in 2022, banks’…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
49
SMTC alert for Mar 17
Semtech [SMTC] is down 0.49% over the past day.
Buy
62
PLPC alert for Mar 17
Preformed Line Products [PLPC] is up 3.8% over the past day.
Sell
50
NUTX alert for Mar 17
Nutex Health [NUTX] is up 4.82% over the past day.
